title: Transient mesenteric ischemia leads to remodeling of rat mesenteric resistance arteries.
abstract: Mesenteric ischemia/reperfusion (I/R) is associated with high rates of morbidity and mortality. We studied the effect of mesenteric I/R on structural and mechanical properties of rat mesenteric resistance artery (MRA) that, once disrupted, might impact the outcome of this devastating clinical condition. Superior mesenteric artery from Wistar-Kyoto rats was occluded (90 min) and reperfused (24 h). The effect of tezosentan, a dual endothelin (ET)-receptor antagonist, was studied in ischemic (IO) and sham-operated (SO) animals. MRA structure and mechanics were assessed by pressure myography. Nuclei distribution, elastin content and organization, collagen I/III and ET-1 expression, ET-1 plasma levels, superoxide anion ([Formula: see text]) production, and mRNA levels of NAD(P)H-oxidase subunits were measured. To assess ET-1 effects on [Formula: see text] production, MRA from non-operated rats were incubated in culture medium with ET-1. Mesenteric I/R increased MRA wall thickness (P < 0.05) and cross-sectional area (P < 0.05) but decreased wall stiffness (P < 0.05). Arterial remodeling was paralleled by enhancement of: (i) collagen I/III expression (P < 0.01), ET-1 expression (P < 0.05), and [Formula: see text] formation (P < 0.01) in the vessel wall; (ii) number of internal elastic lamina (IEL) fenestrae (P < 0.05); and (iii) plasma levels of ET-1 (P < 0.05). Moreover, ET-1 increased [Formula: see text] (P < 0.05) production in cultured MRA. Tezosentan prevented hypertrophic remodeling and collagen I/III deposition, and enhanced [Formula: see text] production, but it did not affect the decreased wall stiffness after mesenteric I/R. These results indicate that 90 min occlusion/24 h reperfusion induces hypertrophic remodeling of MRA linked to ET-1-mediated increase of collagen and [Formula: see text]. Decreased stiffness may be associated with increased number of IEL fenestrae. The resulting MRA remodeling, initially adaptive, might become maladaptive contributing to the pathology and poor outcome of mesenteric I/R, and might be a valuable treatment target for mesenteric I/R.
authors.affiliation: Departament de Farmacologia, Terapèutica i Toxicología, Universitat Autònoma de Barcelona Barcelona, Spain.
authors.forename: Laura
authors.initials: L
authors.lastname: Caracuel
authors.forename: Francesc
authors.initials: F
authors.lastname: Jiménez-Altayó
authors.forename: Mónica
authors.initials: M
authors.lastname: Romo
authors.forename: Ana
authors.initials: A
authors.lastname: Márquez-Martín
authors.forename: Ana P
authors.initials: AP
authors.lastname: Dantas
authors.forename: Elisabet
authors.initials: E
authors.lastname: Vila